1 Min Read
Oct 19 (Reuters) - Valeant Pharmaceuticals International Inc , which is under fire for massive price hikes of its two heart drugs, reported a 36 percent rise in quarterly revenue, as sales of dermatology products rose in the United States.
Net income attributable to the Canadian drugmaker fell to $49.5 million, or 14 cents per share, for the third quarter ended Sept. 30, from $275.4 million, or 81 cents per share, a year earlier.
Revenue rose to $2.79 billion from $2.06 billion.
Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D'Silva